Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 183 participants.
Also called NCT06872684
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 183 participants
- Sponsor
- Registry
-
NCT06872684
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT06872684. Allocation not applicable; no masking; primary purpose treatment. Start 2025-06-20 (actual); primary completion 2029-01-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)
- Acronym
- GUARD
- Condition
- Aneurysm
- Condition
- Aneurysm, Intracranial
- Intervention (Device)
- Surpass Elite with Guardian Flow Diverter System
- Lead sponsor
- Stryker Neurovascular
Record details
- Record id
cardio:ct-nct06872684- Content hash
200bb99bd957b495118d89caa6724e215f6989773f27f47e8de2fdbff670992f